29 January 2015 - The Japanese Pharmaceuticals and Medical Devices Agency has cleared the use of Swedish medical products company Aerocrine AB's (STO: AEROB) Niox Vero FeNO-measuring device as a tool for assessing patients with allergic airway inflammation such as asthma, the company said.

According to the company, Niox Vero will be introduced on the Japanese market in the beginning of 2Q15.

Niox Vero is the company's next generation device for measuring Fractional Nitric Oxide levels in clinical settings. The clearance in Japan follows the FDA approval in the US in November 2014.

The Niox Vero was CE marked in the EU in September 2013. Aerocrine´s Niox Vero and now Niox Vero are the only FeNO measuring devices cleared by both the PMDA in Japan and also FDA in the United States.

Aerocrine said that the Niox Vero has been developed in cooperation with Japanese electronics company Panasonic's Panasonic Healthcare Co., Ltd. subsidiary.

Under the agreement, Aerocrine and Panasonic Healthcare will collaborate to develop products for airway inflammation monitoring for both clinical and personal use. Panasonic Healthcare will be responsible for the worldwide manufacture and supply of the devices and filters and Aerocrine will be responsible for regulatory approvals, method development and global commercialization.

Aerocrine is a medical products company focused on improved management and care of patients with inflammatory airway diseases such as asthma.